Aktienanalyse zu Dr Reddy's Laboratories Ltd (RDY)RDYDr Reddy's Laboratories Ltd

Dr. Reddy’s Laboratories Limited is an India-based pharmaceutical company. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Dr Reddy's Laboratories Ltd is not a good buy right now due to a recent downgrade from Goldman Sachs, which set a price target of INR 1,075, significantly lower than the current price of $12.18. Additionally, the company's last earnings report showed an EPS of 0.06, which was a 64.71% miss from the expected 0.17, indicating potential ongoing financial struggles. The RSI is currently at 47.072, suggesting the stock is neither overbought nor oversold, but the lack of upward momentum and negative analyst sentiment point to a sell recommendation.

1 analysts cover RDY: 0 rate it Buy, 0 Hold and 1 Sell.